Back to results
US 2023/0147799 A1Published application
Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereof
AssigneeEliem Therapeutics (UK) Ltd
InventorsAndrew D. Levin, Neil Buckley
Life of this patent
Estimating the term…
Abstract
The invention provides compositions containing isomerically pure forms of neurosteroids that permit preferential modulation of different subtypes of GABAA receptors, such as preferential modulation of α4β3δ GABAA receptors over α1β2γ2 GABAA receptors. The invention also provides methods of treating GABAA disorders using such compositions.
Claims10
A method for treating a GABAA disorder, the method comprising providing to a subject having a GABAA disorder a pharmaceutical composition comprising an isomerically pure form of a compound of Formula (I):
- wherein the compound of Formula (I) is present in a therapeutically effective amount to preferentially potentiate an α4β3δ GABAA receptor as compared to an α1β2γ2 GABAA receptor.
Dependencies are inferred from the claim text.